Given the importance of the PD-1/PD-L1 pathway in islet-specific T cell tolerance, some investigators are using techniques of genetic engineering to generate β cells that would be immunologically “privileged” to be used for β cell replacement in T1D patients (113, 114). This evidence concerns the gene CD274 and type 1 diabetes mellitus.